JP2018532807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532807A5 JP2018532807A5 JP2018543077A JP2018543077A JP2018532807A5 JP 2018532807 A5 JP2018532807 A5 JP 2018532807A5 JP 2018543077 A JP2018543077 A JP 2018543077A JP 2018543077 A JP2018543077 A JP 2018543077A JP 2018532807 A5 JP2018532807 A5 JP 2018532807A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- inden
- imidazole
- pharmaceutical composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- -1 1H-inden-2-yl Chemical group 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 210000003050 axon Anatomy 0.000 claims 3
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 210000004126 nerve fiber Anatomy 0.000 claims 3
- 230000036407 pain Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical group CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960005139 epinephrine Drugs 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- RAIOHQDCXSHSDF-UHFFFAOYSA-N 1-(1,2,3,4-tetrahydronaphthalen-2-yl)imidazole Chemical compound C1CC2=CC=CC=C2CC1N1C=CN=C1 RAIOHQDCXSHSDF-UHFFFAOYSA-N 0.000 claims 1
- YDLNAYOZHQDDTH-UHFFFAOYSA-N 1-[2-(1h-imidazol-5-yl)-1,3-dihydroinden-2-yl]ethanol Chemical compound C1C2=CC=CC=C2CC1(C(O)C)C1=CN=CN1 YDLNAYOZHQDDTH-UHFFFAOYSA-N 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- YSTYCHLBWJMTKH-UHFFFAOYSA-N 2-(1H-imidazol-5-yl)-1,3-dihydroindene-2-carbonitrile Chemical compound N1C=NC=C1C1(CC2=CC=CC=C2C1)C#N YSTYCHLBWJMTKH-UHFFFAOYSA-N 0.000 claims 1
- HNYFGBAQPKQXPB-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)-2-methyl-1,3-dihydroinden-5-amine Chemical compound C1C2=CC=C(N)C=C2CC1(C)C1=CNC=N1 HNYFGBAQPKQXPB-UHFFFAOYSA-N 0.000 claims 1
- LCQUJXODSUQFBV-UHFFFAOYSA-N 5-(1,2,3,4-tetrahydronaphthalen-1-yl)-1h-imidazole Chemical compound C12=CC=CC=C2CCCC1C1=CNC=N1 LCQUJXODSUQFBV-UHFFFAOYSA-N 0.000 claims 1
- JUVLKUBXUALSMA-UHFFFAOYSA-N 5-(1-methyl-2,3-dihydroinden-1-yl)-1h-imidazole Chemical compound C1CC2=CC=CC=C2C1(C)C1=CNC=N1 JUVLKUBXUALSMA-UHFFFAOYSA-N 0.000 claims 1
- DNZFCHAQKMVPEJ-UHFFFAOYSA-N 5-(2,5-dimethyl-1,3-dihydroinden-2-yl)-1H-imidazole Chemical compound N1C=C(C2(CC3=C(C=CC(C)=C3)C2)C)N=C1 DNZFCHAQKMVPEJ-UHFFFAOYSA-N 0.000 claims 1
- RCRUVEMWFDEMQM-UHFFFAOYSA-N 5-(2-ethenyl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=CC=C2CC1(C=C)C1=CN=CN1 RCRUVEMWFDEMQM-UHFFFAOYSA-N 0.000 claims 1
- BJLHXEIHYYPKNR-UHFFFAOYSA-N 5-(2-ethyl-5,6-difluoro-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC(F)=C(F)C=C2CC1(CC)C1=CNC=N1 BJLHXEIHYYPKNR-UHFFFAOYSA-N 0.000 claims 1
- KXSUAWAUCNFBQJ-UHFFFAOYSA-N 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=C(F)C=C2CC1(CC)C1=CN=CN1 KXSUAWAUCNFBQJ-UHFFFAOYSA-N 0.000 claims 1
- GSYASXGKPINEHP-UHFFFAOYSA-N 5-(2-ethyl-5-methyl-1,3-dihydroinden-2-yl)-1H-imidazole Chemical compound C(C)C1(CC2=CC=C(C=C2C1)C)C1=CN=CN1 GSYASXGKPINEHP-UHFFFAOYSA-N 0.000 claims 1
- GSTMIZOKPPLPMB-UHFFFAOYSA-N 5-(2-ethyl-5-nitro-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=C([N+]([O-])=O)C=C2CC1(CC)C1=CNC=N1 GSTMIZOKPPLPMB-UHFFFAOYSA-N 0.000 claims 1
- SXFUFEJGXKJXRN-UHFFFAOYSA-N 5-(2-prop-1-en-2-yl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=CC=C2CC1(C(=C)C)C1=CN=CN1 SXFUFEJGXKJXRN-UHFFFAOYSA-N 0.000 claims 1
- GDOPFLWTUPGRTB-UHFFFAOYSA-N 5-(2-propan-2-yl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=CC=C2CC1(C(C)C)C1=CN=CN1 GDOPFLWTUPGRTB-UHFFFAOYSA-N 0.000 claims 1
- FYUWKMBWIIYZOI-UHFFFAOYSA-N 5-(5,6-dichloro-2-ethyl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC(Cl)=C(Cl)C=C2CC1(CC)C1=CNC=N1 FYUWKMBWIIYZOI-UHFFFAOYSA-N 0.000 claims 1
- OCMFMSSLORYDGK-UHFFFAOYSA-N 5-(5-chloro-2-ethyl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=C(Cl)C=C2CC1(CC)C1=CNC=N1 OCMFMSSLORYDGK-UHFFFAOYSA-N 0.000 claims 1
- CSHJUAVQSHDWOT-UHFFFAOYSA-N 5-(5-chloro-2-ethyl-6-fluoro-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC(F)=C(Cl)C=C2CC1(CC)C1=CNC=N1 CSHJUAVQSHDWOT-UHFFFAOYSA-N 0.000 claims 1
- TYKJDVOAYDJWAD-UHFFFAOYSA-N 5-(5-fluoro-2-methyl-1,3-dihydroinden-2-yl)-1h-imidazole Chemical compound C1C2=CC=C(F)C=C2CC1(C)C1=CNC=N1 TYKJDVOAYDJWAD-UHFFFAOYSA-N 0.000 claims 1
- DNMPMKVBCPFIQP-UHFFFAOYSA-N 5-(5-methyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole Chemical compound CC=1C=C2CC(CC2=CC=1)C1=CN=CN1 DNMPMKVBCPFIQP-UHFFFAOYSA-N 0.000 claims 1
- DRDCOTIVJPTPCX-UHFFFAOYSA-N 5-[2-(methoxymethyl)-1,3-dihydroinden-2-yl]-1h-imidazole Chemical compound C1C2=CC=CC=C2CC1(COC)C1=CNC=N1 DRDCOTIVJPTPCX-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical group CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 claims 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 1
- GFZDAPZEORQWCB-UHFFFAOYSA-N [2-(1h-imidazol-5-yl)-1,3-dihydroinden-2-yl]methanol Chemical compound C1C2=CC=CC=C2CC1(CO)C1=CNC=N1 GFZDAPZEORQWCB-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229960003831 articaine Drugs 0.000 claims 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 229960004741 cyclomethycaine Drugs 0.000 claims 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- 229960002773 hyaluronidase Drugs 0.000 claims 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002262 irrigation Effects 0.000 claims 1
- 238000003973 irrigation Methods 0.000 claims 1
- 229960004288 levobupivacaine Drugs 0.000 claims 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940053973 novocaine Drugs 0.000 claims 1
- 229960001045 piperocaine Drugs 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 229960003981 proparacaine Drugs 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 210000001044 sensory neuron Anatomy 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims 1
- 229950002569 trimecaine Drugs 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021169040A JP2022009155A (ja) | 2015-11-05 | 2021-10-14 | 局所と局部の麻酔と鎮痛 |
| JP2023184958A JP2024012412A (ja) | 2015-11-05 | 2023-10-27 | 局所と局部の麻酔と鎮痛 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251162P | 2015-11-05 | 2015-11-05 | |
| US62/251,162 | 2015-11-05 | ||
| PCT/US2016/060802 WO2017079734A1 (en) | 2015-11-05 | 2016-11-07 | Local and regional anesthesia and analgesia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169040A Division JP2022009155A (ja) | 2015-11-05 | 2021-10-14 | 局所と局部の麻酔と鎮痛 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532807A JP2018532807A (ja) | 2018-11-08 |
| JP2018532807A5 true JP2018532807A5 (enExample) | 2019-12-19 |
| JP7002756B2 JP7002756B2 (ja) | 2022-01-20 |
Family
ID=58662510
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543077A Active JP7002756B2 (ja) | 2015-11-05 | 2016-11-07 | 局所と局部の麻酔と鎮痛 |
| JP2021169040A Pending JP2022009155A (ja) | 2015-11-05 | 2021-10-14 | 局所と局部の麻酔と鎮痛 |
| JP2023184958A Pending JP2024012412A (ja) | 2015-11-05 | 2023-10-27 | 局所と局部の麻酔と鎮痛 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169040A Pending JP2022009155A (ja) | 2015-11-05 | 2021-10-14 | 局所と局部の麻酔と鎮痛 |
| JP2023184958A Pending JP2024012412A (ja) | 2015-11-05 | 2023-10-27 | 局所と局部の麻酔と鎮痛 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12414937B2 (enExample) |
| EP (1) | EP3370718B1 (enExample) |
| JP (3) | JP7002756B2 (enExample) |
| ES (1) | ES2861502T3 (enExample) |
| WO (1) | WO2017079734A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020245203A1 (en) * | 2019-03-26 | 2021-11-11 | Martin Uram | Anesthetic composition and method of anesthetizing the eye |
| JP6886551B1 (ja) * | 2020-11-06 | 2021-06-16 | 医療法人祥和会 | 歯科用の局所麻酔液 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1261499A (en) | 1984-11-22 | 1989-09-26 | Tatsuo Kinoshita | Modified ethylenic random copolymer |
| GB2167408B (en) * | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| GB9127050D0 (en) * | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| US6733982B1 (en) * | 1999-03-17 | 2004-05-11 | Syntex (U.S.A.) Llc | Method for screening compounds for alpha1B adrenergic receptor antagonist and analgesic activity |
| US20030082225A1 (en) * | 2001-10-19 | 2003-05-01 | Mason Paul Arthur | Sterile, breathable patch for treating wound pain |
| WO2006014484A2 (en) * | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
| EP2219449A4 (en) * | 2007-11-16 | 2010-10-27 | Univ Arizona State | METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING |
-
2016
- 2016-11-07 US US15/772,609 patent/US12414937B2/en active Active
- 2016-11-07 WO PCT/US2016/060802 patent/WO2017079734A1/en not_active Ceased
- 2016-11-07 JP JP2018543077A patent/JP7002756B2/ja active Active
- 2016-11-07 ES ES16863158T patent/ES2861502T3/es active Active
- 2016-11-07 EP EP16863158.8A patent/EP3370718B1/en active Active
-
2021
- 2021-10-14 JP JP2021169040A patent/JP2022009155A/ja active Pending
-
2023
- 2023-10-27 JP JP2023184958A patent/JP2024012412A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7005668B2 (ja) | 弾性ポリマー－薬物マトリックス系を含む膀胱内薬物送達デバイス | |
| JP6694497B2 (ja) | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 | |
| Delage et al. | Median effective dose (ED50) of nefopam and ketoprofen in postoperative patients: a study of interaction using sequential analysis and isobolographic analysis | |
| AU2010100050A4 (en) | A topical analgesic composition | |
| US5840755A (en) | Method and composition for topical therapy of headaches | |
| JP2018522905A5 (enExample) | ||
| JP2010522738A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| CA2465132A1 (en) | Vaginally administered anti-dysrhythmic agents for treating pelvic pain | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| Yu et al. | The development of local anesthetics and their applications beyond anesthesia | |
| JP2018532807A5 (enExample) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| EP4574822A3 (en) | Compounds and compositions for use in treating skin disorders | |
| JP2023517604A (ja) | 荷電したイオンチャンネル遮断薬および使用方法 | |
| WO2009096701A3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| TW200716522A (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| CN114177133A (zh) | 一种药物缓释载体、缓释药物组合物及其应用 | |
| RU2012119247A (ru) | Модуляторы альфа-адренергических рецепторов | |
| JP2024012412A (ja) | 局所と局部の麻酔と鎮痛 | |
| RU2013157834A (ru) | Композиции для подкожного введения физиологически активных средств | |
| JP2021535170A5 (enExample) | ||
| Chen et al. | The addition of epinephrine to proxymetacaine or oxybuprocaine solution increases the depth and duration of cutaneous analgesia in rats | |
| JP2020530023A5 (enExample) | ||
| RU2013129485A (ru) | Новые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) |